AR030523A1 - Compuestos 1,2,3,4-tetrahidroquinolinas 2-sustituidas 4-amino sustituidas, su uso en la preparacion de medicamentos, composiciones farmaceuticas, y equipo que los contiene. - Google Patents
Compuestos 1,2,3,4-tetrahidroquinolinas 2-sustituidas 4-amino sustituidas, su uso en la preparacion de medicamentos, composiciones farmaceuticas, y equipo que los contiene.Info
- Publication number
- AR030523A1 AR030523A1 ARP990104554A ARP990104554A AR030523A1 AR 030523 A1 AR030523 A1 AR 030523A1 AR P990104554 A ARP990104554 A AR P990104554A AR P990104554 A ARP990104554 A AR P990104554A AR 030523 A1 AR030523 A1 AR 030523A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituted
- optionally
- optionally mono
- oxo
- mono
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 239000003814 drug Substances 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 37
- 229910052757 nitrogen Inorganic materials 0.000 abstract 28
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 26
- 229920006395 saturated elastomer Polymers 0.000 abstract 26
- 125000004043 oxo group Chemical group O=* 0.000 abstract 23
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 19
- 229910052717 sulfur Inorganic materials 0.000 abstract 19
- 239000011593 sulfur Substances 0.000 abstract 19
- 229910052799 carbon Inorganic materials 0.000 abstract 17
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 14
- 229910052760 oxygen Inorganic materials 0.000 abstract 14
- 239000001301 oxygen Substances 0.000 abstract 14
- 125000005843 halogen group Chemical group 0.000 abstract 13
- 125000005842 heteroatom Chemical group 0.000 abstract 13
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 13
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 8
- 125000004414 alkyl thio group Chemical group 0.000 abstract 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 5
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 4
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 4
- 125000002619 bicyclic group Chemical group 0.000 abstract 4
- 125000001424 substituent group Chemical group 0.000 abstract 4
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 abstract 3
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 125000001153 fluoro group Chemical group F* 0.000 abstract 3
- 239000003112 inhibitor Substances 0.000 abstract 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 3
- 102000012336 Cholesterol Ester Transfer Proteins Human genes 0.000 abstract 2
- 108010061846 Cholesterol Ester Transfer Proteins Proteins 0.000 abstract 2
- 238000008214 LDL Cholesterol Methods 0.000 abstract 2
- 125000003342 alkenyl group Chemical group 0.000 abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 150000002632 lipids Chemical class 0.000 abstract 2
- 239000000651 prodrug Substances 0.000 abstract 2
- 229940002612 prodrug Drugs 0.000 abstract 2
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 abstract 2
- 150000003626 triacylglycerols Chemical class 0.000 abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 1
- 108010023302 HDL Cholesterol Proteins 0.000 abstract 1
- 108010010234 HDL Lipoproteins Proteins 0.000 abstract 1
- 102000015779 HDL Lipoproteins Human genes 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 235000012000 cholesterol Nutrition 0.000 abstract 1
- -1 cyano, formyl Chemical group 0.000 abstract 1
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 239000011737 fluorine Substances 0.000 abstract 1
- 125000005740 oxycarbonyl group Chemical group [*:1]OC([*:2])=O 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 abstract 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
- C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Communicable Diseases (AREA)
- Child & Adolescent Psychology (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10092798P | 1998-09-17 | 1998-09-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR030523A1 true AR030523A1 (es) | 2003-08-27 |
Family
ID=22282246
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP990104554A AR030523A1 (es) | 1998-09-17 | 1999-09-10 | Compuestos 1,2,3,4-tetrahidroquinolinas 2-sustituidas 4-amino sustituidas, su uso en la preparacion de medicamentos, composiciones farmaceuticas, y equipo que los contiene. |
Country Status (50)
Families Citing this family (130)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GT199900147A (es) * | 1998-09-17 | 1999-09-06 | 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas. | |
| US6147089A (en) * | 1998-09-17 | 2000-11-14 | Pfizer Inc. | Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines |
| US6197786B1 (en) * | 1998-09-17 | 2001-03-06 | Pfizer Inc | 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines |
| US7115279B2 (en) * | 2000-08-03 | 2006-10-03 | Curatolo William J | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors |
| US20060287254A1 (en) * | 2001-01-26 | 2006-12-21 | Schering Corporation | Use of substituted azetidinone compounds for the treatment of sitosterolemia |
| SE0101161D0 (sv) | 2001-03-30 | 2001-03-30 | Astrazeneca Ab | New compounds |
| US20030064967A1 (en) * | 2001-04-11 | 2003-04-03 | Jayraz Luchoomun | Methods to increase plasma HDL cholesterol levels and improve HDL functionality with probucol monoesters |
| CZ20032900A3 (cs) * | 2001-04-30 | 2004-06-16 | Pfizer Products Inc. | Sloučeniny vhodné jako meziprodukty |
| EP1453544A2 (en) * | 2001-06-21 | 2004-09-08 | Pfizer Products Inc. | Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors |
| EP1269994A3 (en) | 2001-06-22 | 2003-02-12 | Pfizer Products Inc. | Pharmaceutical compositions comprising drug and concentration-enhancing polymers |
| HUP0400281A3 (en) | 2001-06-22 | 2009-11-30 | Pfizer Prod Inc | Pharmaceutical compositions of adsorbates of amorphous drug and process for their preparation |
| BR0210518A (pt) * | 2001-06-22 | 2004-06-22 | Pfizer Prod Inc | Composições farmacêuticas de dispersões de drogas e polìmeros neutros |
| WO2003053368A2 (en) * | 2001-12-19 | 2003-07-03 | Atherogenics, Inc. | Chalcone derivatives and their use to treat diseases |
| WO2003053359A2 (en) | 2001-12-19 | 2003-07-03 | Atherogenics, Inc. | 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders |
| HUP0402309A3 (en) * | 2001-12-21 | 2008-09-29 | Novo Nordisk As | Amide derivatives as glucokinase activators and pharmaceutical compositions containing them |
| RU2004123637A (ru) * | 2002-02-01 | 2005-04-20 | Пфайзер Продактс Инк. (Us) | Фармацевтические лекарственные формы контролируемого высвобождения ингибитора транспортного белка холестерилового |
| JP2005523262A (ja) | 2002-02-01 | 2005-08-04 | ファイザー・プロダクツ・インク | 薬物及び親油性ミクロ相形成物質の非晶質分散物の医薬組成物 |
| AR038375A1 (es) | 2002-02-01 | 2005-01-12 | Pfizer Prod Inc | Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo |
| PT1469833T (pt) * | 2002-02-01 | 2021-07-13 | Bend Res Inc | Método para produzir dispersões de fármaco amorfo sólido seco por pulverização homogéneas utilizando aparelho de secagem por pulverização modificado |
| BR0312023A (pt) * | 2002-06-27 | 2005-03-22 | Novo Nordisk As | Composto, composto ativador da glicose cinase, método para evitar a hipoglicemia, uso de um composto, e, composição farmacêutica |
| US20040053842A1 (en) * | 2002-07-02 | 2004-03-18 | Pfizer Inc. | Methods of treatment with CETP inhibitors and antihypertensive agents |
| US7071210B2 (en) * | 2002-07-02 | 2006-07-04 | Pfizer Inc. | CETP inhibitors in combination with antihypertensive agents and uses thereof |
| US7504508B2 (en) | 2002-10-04 | 2009-03-17 | Millennium Pharmaceuticals, Inc. | PGD2 receptor antagonists for the treatment of inflammatory diseases |
| EP1556047A4 (en) | 2002-10-04 | 2009-09-30 | Millennium Pharm Inc | ANTAGONISTS AGAINST THE PGD2 RECEPTOR FOR THE TREATMENT OF INFLAMMATORY DISEASES |
| US20090181966A1 (en) * | 2002-10-04 | 2009-07-16 | Millennium Pharmaceuticals, Inc. | PGD2 receptor antagonists for the treatment of inflammatory diseases |
| ATE327977T1 (de) * | 2002-10-21 | 2006-06-15 | Warner Lambert Co | Tetrahydrochinolin-derivate als crth2 antagonisten |
| WO2004052863A1 (ja) * | 2002-12-06 | 2004-06-24 | Kyowa Hakko Kogyo Co., Ltd. | 抗炎症剤 |
| WO2004056727A2 (en) * | 2002-12-19 | 2004-07-08 | Atherogenics, Inc. | Process of making chalcone derivatives |
| BR0317521A (pt) | 2002-12-20 | 2005-11-16 | Pfizer Prod Inc | Formas de dosagem compreendendo um inibidor da cetp e um inibidor da redutase hmg-coa |
| US20040132771A1 (en) * | 2002-12-20 | 2004-07-08 | Pfizer Inc | Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors |
| EP1435356A1 (en) * | 2003-01-06 | 2004-07-07 | Warner-Lambert Company LLC | Quinoline derivatives as CRTH2 antagonists |
| WO2004072042A2 (en) * | 2003-02-12 | 2004-08-26 | Carex S.A. | Quinoline derivative and their use for modulation of lxr activity |
| EP1603554A1 (en) * | 2003-03-17 | 2005-12-14 | Japan Tobacco Inc. | Method for increasing the oral bioavailability of s-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl]-2-methylpropanethioate |
| KR100857759B1 (ko) | 2003-03-17 | 2008-09-09 | 니뽄 다바코 산교 가부시키가이샤 | Ｃｅｔｐ 억제제의 약제학적 조성물 |
| EA200501376A1 (ru) * | 2003-03-28 | 2006-04-28 | Пфайзер Продактс Инк. | Производные 1,2,4-замещённых 1,2,3,4-тетрагидро- и 1,2-дигидрохинолинов и 1,2,3,4-тетрагидрохиноксалина в качестве ингибиторов сетр для лечения атеросклероза и тучности |
| US20040204450A1 (en) * | 2003-03-28 | 2004-10-14 | Pfizer Inc | Quinoline and quinoxaline compounds |
| TWI393560B (zh) * | 2003-05-02 | 2013-04-21 | Japan Tobacco Inc | 包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合 |
| KR20110117731A (ko) | 2003-05-30 | 2011-10-27 | 랜박시 래보러터리스 리미티드 | 치환된 피롤 유도체와 ｈｍｇ―ｃｏ 억제제로서의 이의 용도 |
| BRPI0413277A (pt) * | 2003-08-04 | 2006-10-10 | Pfizer Prod Inc | composições farmacêuticas de adsorvatos de medicamentos amorfos e materiais que formam microfases lipofìlicas |
| CL2004001884A1 (es) | 2003-08-04 | 2005-06-03 | Pfizer Prod Inc | Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros. |
| WO2005030185A2 (en) | 2003-09-26 | 2005-04-07 | Japan Tobacco Inc. | Method of inhibiting remnant lipoprotein production |
| BRPI0414671A (pt) * | 2003-09-30 | 2006-11-21 | Pfizer Prod Inc | inibidores da cetp e metabolitos dos mesmos |
| DK1670768T3 (da) | 2003-10-08 | 2009-11-09 | Lilly Co Eli | Forbindelser og fremgangsmåder til at behandle dyslipidæmi |
| CA2543596A1 (en) * | 2003-11-07 | 2005-05-26 | Jj Pharma, Inc. | Hdl-boosting combination therapy complexes |
| DK1723128T3 (da) * | 2004-01-06 | 2013-02-18 | Novo Nordisk As | Heteroarylurinstoffer og deres anvendelse som glucokinaseaktivatorer |
| CA2558766A1 (en) | 2004-03-05 | 2005-09-22 | The Trustees Of The University Of Pennsylvania | The use of mtp inhibitors for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects |
| US7262318B2 (en) * | 2004-03-10 | 2007-08-28 | Pfizer, Inc. | Substituted heteroaryl- and phenylsulfamoyl compounds |
| ATE402180T1 (de) | 2004-03-26 | 2008-08-15 | Lilly Co Eli | Verbindungen zur behandlung von dyslipidemie |
| MY139887A (en) * | 2004-04-02 | 2009-11-30 | Mitsubishi Tanabe Pharma Corp | Tetrahydronaphthyridine derivatives and a process for preparing the same. |
| UA90269C2 (ru) * | 2004-04-02 | 2010-04-26 | Мицубиси Танабе Фарма Корпорейшн | Тетрагидрохинолиновые производные и способ их получения |
| US20050282812A1 (en) * | 2004-06-18 | 2005-12-22 | JONES Zachary | Inhibitors of cholesteryl ester transfer protein |
| KR100859223B1 (ko) * | 2004-06-24 | 2008-09-18 | 일라이 릴리 앤드 캄파니 | 이상지혈증 치료를 위한 화합물 및 방법 |
| JP2008504266A (ja) * | 2004-06-24 | 2008-02-14 | イーライ リリー アンド カンパニー | 異脂肪血症を治療するための化合物及び方法 |
| US20060063828A1 (en) * | 2004-06-28 | 2006-03-23 | Weingarten M D | 1,2-Bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof |
| US20050288340A1 (en) * | 2004-06-29 | 2005-12-29 | Pfizer Inc | Substituted heteroaryl- and phenylsulfamoyl compounds |
| DOP2005000123A (es) | 2004-07-02 | 2011-07-15 | Merck Sharp & Dohme | Inhibidores de cetp |
| ATE463249T1 (de) * | 2004-08-25 | 2010-04-15 | Essentialis Inc | Pharmazeutische formulierungen von kalium-atp- kanalöffnern und deren verwendungen |
| US20060063803A1 (en) * | 2004-09-23 | 2006-03-23 | Pfizer Inc | 4-Amino substituted-2-substituted-1,2,3,4-tetrahydroquinoline compounds |
| US20070149567A1 (en) * | 2004-09-23 | 2007-06-28 | Pfizer Inc | Quinoline compounds |
| KR20070084455A (ko) * | 2004-11-23 | 2007-08-24 | 워너-램버트 캄파니 엘엘씨 | 지질혈증 치료용 ｈｍｇ ｃｏ-ａ 환원효소 억제제로서의7-(2ｈ-피라졸-3-일)-3,5-디히드록시-헵탄산 유도체 |
| WO2006069162A1 (en) * | 2004-12-20 | 2006-06-29 | Reddy Us Therapeutics, Inc. | Novel heterocyclic compounds and their pharmaceutical compositions |
| CA2605214C (en) | 2004-12-31 | 2016-07-12 | Reddy Us Therapeutics, Inc. | Benzylamine derivatives as cetp inhibitors |
| US8604055B2 (en) | 2004-12-31 | 2013-12-10 | Dr. Reddy's Laboratories Ltd. | Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors |
| WO2006082518A1 (en) | 2005-02-03 | 2006-08-10 | Pfizer Products Inc. | Pharmaceutical compositions with enhanced performance |
| MX2007010215A (es) | 2005-02-24 | 2007-11-07 | Millennium Pharm Inc | Antagonistas del receptor pgd2 para el tratamiento de enfermedades inflamatorias. |
| WO2006098394A1 (ja) * | 2005-03-14 | 2006-09-21 | Japan Tobacco Inc. | 脂質吸収抑制方法および脂質吸収抑制剤 |
| CA2612142A1 (en) * | 2005-07-01 | 2007-01-11 | Merck & Co., Inc. | Process for synthesizing a cetp inhibitor |
| JP2009500378A (ja) * | 2005-07-08 | 2009-01-08 | ノボ・ノルデイスク・エー／エス | グルコキナーゼ活性化剤としてのジシクロアルキルカルバモイル尿素 |
| CA2614518A1 (en) * | 2005-07-08 | 2007-01-18 | Novo-Nordisk A/S | Dicycloalkyl urea glucokinase activators |
| EP2377856A1 (en) | 2005-07-14 | 2011-10-19 | Novo Nordisk A/S | Urea glucokinase activators |
| GT200600381A (es) | 2005-08-25 | 2007-03-28 | Compuestos organicos | |
| JP4531027B2 (ja) * | 2005-09-29 | 2010-08-25 | 田辺三菱製薬株式会社 | 医薬組成物 |
| JP4681526B2 (ja) * | 2005-09-29 | 2011-05-11 | 田辺三菱製薬株式会社 | 医薬組成物 |
| EP1940374A2 (en) | 2005-10-21 | 2008-07-09 | Novartis AG | Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent |
| AU2006313430B2 (en) | 2005-11-08 | 2012-09-06 | Ranbaxy Laboratories Limited | Process for (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt |
| US7888376B2 (en) | 2005-11-23 | 2011-02-15 | Bristol-Myers Squibb Company | Heterocyclic CETP inhibitors |
| EP1968601B1 (en) | 2006-01-05 | 2011-10-19 | Essentialis, Inc. | Salts of potassium atp channel openers and uses thereof |
| PE20071025A1 (es) | 2006-01-31 | 2007-10-17 | Mitsubishi Tanabe Pharma Corp | Compuesto amina trisustituido |
| UY30117A1 (es) | 2006-01-31 | 2007-06-29 | Tanabe Seiyaku Co | Compuesto amina trisustituido |
| UY30244A1 (es) | 2006-03-30 | 2007-11-30 | Tanabe Seiyaku Co | Un proceso para preparar derivados de tetrahidroquinolina |
| GB0615670D0 (en) * | 2006-08-07 | 2006-09-13 | Syngenta Participations Ag | Chemical compounds |
| US7750019B2 (en) | 2006-08-11 | 2010-07-06 | Kowa Company, Ltd. | Pyrimidine compound having benzyl(pyridylmethyl)amine structure and medicament comprising the same |
| US20100210633A1 (en) * | 2006-10-12 | 2010-08-19 | Epix Delaware, Inc. | Carboxamide compounds and their use |
| EP2094643B1 (en) | 2006-12-01 | 2012-02-29 | Bristol-Myers Squibb Company | N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-amine derivatives as cetp inhibitors for the treatment of atherosclerosis and cardiovascular diseases |
| AU2007338625A1 (en) * | 2006-12-21 | 2008-07-03 | Aegerion Pharmaceuticals, Inc. | Methods for treating obesity with a combination comprising a MTP inhibitor and a cholesterol absorption inhibitor |
| JP2010515701A (ja) * | 2007-01-09 | 2010-05-13 | ノボ・ノルデイスク・エー／エス | ウレアグルコキナーゼアクチベーター |
| AU2008204530B2 (en) * | 2007-01-11 | 2013-08-01 | Vtv Therapeutics Llc | Urea glucokinase activators |
| CN101220021B (zh) * | 2007-01-12 | 2010-12-08 | 上海医药工业研究院 | 4-取代苯氧基喹啉类化合物及其中间体、制备方法和应用 |
| US7790737B2 (en) | 2007-03-13 | 2010-09-07 | Kowa Company, Ltd. | Substituted pyrimidine compounds and their utility as CETP inhibitors |
| DK2149563T3 (en) | 2007-04-13 | 2015-02-02 | Kowa Co | Novel pyrimidine compound with dibenzylaminstruktur, and medicine comprising the compound |
| CA2692160A1 (en) * | 2007-07-02 | 2009-01-08 | Essentialis, Inc. | Salts of potassium atp channel openers and uses thereof |
| AR069165A1 (es) | 2007-11-05 | 2010-01-06 | Novartis Ag | Derivados de 4-bencilamino-1-carboxacilpiperidina como inhibidores de cetp utiles para el tratamiento de hiperlipidemia |
| PL2404901T3 (pl) | 2007-12-03 | 2013-10-31 | Novartis Ag | 1,2-Dipodstawione pochodne 4-benzyloamino-pirolidyny jako inhibitory CETP użyteczne do leczenia chorób, takich jak hiperlipidemia lub stwardnienie tętnic |
| WO2009076512A1 (en) | 2007-12-11 | 2009-06-18 | Epix Delaware, Inc. | Carboxamidξ compounds and their use as chemokine receptor agonists |
| PE20120403A1 (es) | 2009-05-15 | 2012-05-03 | Novartis Ag | Aril-piridinas como inhibidoras de sintasa de aldosterona |
| EA201101621A1 (ru) | 2009-05-15 | 2012-05-30 | Новартис Аг | Производные бензоксазолона в качестве ингибиторов альдостеронсинтазы |
| CN102448928B (zh) | 2009-05-28 | 2014-10-01 | 诺华股份有限公司 | 作为中性溶酶(neprilysin)抑制剂的取代的氨基丁酸衍生物 |
| EP2594557B1 (en) | 2009-05-28 | 2016-08-10 | Novartis AG | Substituted aminopropionic derivatives as neprilysin inhibitors |
| TWI450896B (zh) | 2009-06-30 | 2014-09-01 | Lilly Co Eli | 反式－４－〔〔（５ｓ）－５－〔〔〔３，５－雙（三氟甲基）苯基〕甲基〕（２－甲基－２ｈ－四唑－５－基）胺基〕－２，３，４，５－四氫－７，９－二甲基－１ｈ－１－苯并氮呯－１－基〕甲基〕－環己基羧酸 |
| CN102712589B (zh) | 2009-11-17 | 2015-05-13 | 诺华股份有限公司 | 作为醛固酮合酶抑制剂的芳基-吡啶衍生物 |
| JO2967B1 (en) | 2009-11-20 | 2016-03-15 | نوفارتس ايه جي | Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors |
| EP2507234B1 (en) | 2009-11-30 | 2014-03-12 | Novartis AG | Imidazole derivatives as aldosterone synthase inhibitors |
| JP2013528172A (ja) | 2010-05-21 | 2013-07-08 | ファイザー・インク | ２−フェニルベンゾイルアミド |
| US8877815B2 (en) | 2010-11-16 | 2014-11-04 | Novartis Ag | Substituted carbamoylcycloalkyl acetic acid derivatives as NEP |
| US8673974B2 (en) | 2010-11-16 | 2014-03-18 | Novartis Ag | Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors |
| WO2012101142A1 (en) | 2011-01-26 | 2012-08-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method for assessing a subject's risk of having a cardiovascular disease. |
| WO2012120414A2 (en) | 2011-03-04 | 2012-09-13 | Pfizer Inc. | Edn3-like peptides and uses thereof |
| BR112013032557A2 (pt) | 2011-06-17 | 2020-09-24 | Merck Sharp & Dohe Corp. | composto, formulação farmacêutica, uso de um composto, e, uso de um composto e um agente terap~eutico adicional |
| TWI537262B (zh) * | 2011-08-17 | 2016-06-11 | 美國禮來大藥廠 | 供治療糖尿病使用之新穎１，２，３，４－四氫喹啉衍生物 |
| JP5964965B2 (ja) | 2011-08-18 | 2016-08-03 | ドクター レディズ ラボラトリーズ リミテッド | コレステリルエステル転送タンパク質（ｃｅｔｐ）インヒビターとしての置換複素環式アミン化合物 |
| AU2012313971B2 (en) | 2011-09-27 | 2016-09-29 | Dr. Reddy's Laboratories, Ltd. | 5 - benzylaminomethyl - 6 - aminopyrazolo [3, 4 -b] pyridine derivatives as cholesteryl ester -transfer protein (CETP) inhibitors useful for the treatment of atherosclerosis |
| MX347400B (es) | 2012-06-29 | 2017-04-18 | Univ Nac Autónoma De México | Vacuna de aplicacion nasal contra el desarrollo de la enfermedad aterosclerotica y el higado graso. |
| UY35144A (es) | 2012-11-20 | 2014-06-30 | Novartis Ag | Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca |
| EP2956464B1 (en) | 2013-02-14 | 2018-03-28 | Novartis AG | Substituted bisphenyl butanoic phosphonic acid derivatives as nep (neutral endopeptidase) inhibitors |
| KR101695582B1 (ko) | 2013-04-17 | 2017-01-13 | 화이자 인코포레이티드 | 심혈관 질환을 치료하기 위한 n-피페리딘-3-일벤즈아미드 유도체 |
| HK1218298A1 (zh) | 2013-07-25 | 2017-02-10 | Novartis Ag | 用於治疗心力衰竭的环状多肽 |
| UY35671A (es) | 2013-07-25 | 2015-02-27 | Novartis Ag | Bioconjugados de polipéptidos de apelina sintética |
| CN112755032A (zh) | 2014-08-28 | 2021-05-07 | 狄智玛制药私人有限公司 | 包含胆固醇酯转运蛋白抑制剂和HMG CoA还原酶抑制剂的药物组合物和治疗组合 |
| JP6769963B2 (ja) | 2014-08-29 | 2020-10-14 | ティエエッセ ファルマ ソチエタ レスポンサビリタ リミタータ | α−アミノ−β−カルボキシムコン酸セミアルデヒド脱炭酸酵素の阻害剤 |
| WO2016055901A1 (en) | 2014-10-08 | 2016-04-14 | Pfizer Inc. | Substituted amide compounds |
| CN107406490A (zh) | 2015-01-23 | 2017-11-28 | 诺华股份有限公司 | 具有改善的半衰期的合成apelin脂肪酸缀合物 |
| JOP20190086A1 (ar) | 2016-10-21 | 2019-04-18 | Novartis Ag | مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب |
| UY38072A (es) | 2018-02-07 | 2019-10-01 | Novartis Ag | Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos |
| AU2019287437A1 (en) | 2018-06-12 | 2020-09-10 | Vtv Therapeutics Llc | Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs |
| CN119060040A (zh) | 2019-01-18 | 2024-12-03 | 阿斯利康(瑞典)有限公司 | Pcsk9抑制剂及其使用方法 |
| WO2021167840A1 (en) | 2020-02-18 | 2021-08-26 | Vtv Therapeutics Llc | Sulfoxide and sulfone glucokinase activators and methods of use thereof |
| WO2021252311A1 (en) | 2020-06-08 | 2021-12-16 | Vtv Therapeutics Llc | Salts or co-crystals of {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid and uses thereof |
| AU2021316011A1 (en) | 2020-07-29 | 2023-02-09 | Amryt Pharmaceuticals Inc. | Lomitapide for use in methods of treating hyperlipidemia and hypercholesterolemia in pediatric patients |
| AR127698A1 (es) | 2021-11-23 | 2024-02-21 | Novartis Ag | Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno |
| WO2024241229A1 (en) | 2023-05-24 | 2024-11-28 | Novartis Ag | Naphthyridinone derivatives for the treatment of a disease or disorder |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5231102A (en) * | 1989-03-08 | 1993-07-27 | Merck Sharp & Dohme, Ltd. | Tetrahydroquinoline derivatives useful for neurodegenerative disorders |
| US5276168A (en) * | 1990-06-18 | 1994-01-04 | E. R. Squibb & Sons, Inc. | Benzopyran derivatives and heterocyclic analogs thereof as antiischemic agents |
| US5401848A (en) | 1990-11-26 | 1995-03-28 | E. R. Squibb & Sons, Inc. | Indane and quinoline derivatives |
| KR920014799A (ko) * | 1991-01-18 | 1992-08-25 | 나오가따 다이도 | 신규벤조[5,6]시클로헵타[1,2-b]피리딘 유도체 및 이를 함유하는 항알레르기제 |
| US5288725A (en) * | 1992-10-15 | 1994-02-22 | Merck & Co., Inc. | Pyrroloquinoline Bradykinin antagonist |
| HRP970330B1 (en) * | 1996-07-08 | 2004-06-30 | Bayer Ag | Cycloalkano pyridines |
| DE19627431A1 (de) | 1996-07-08 | 1998-01-15 | Bayer Ag | Heterocyclisch kondensierte Pyridine |
| US6147089A (en) | 1998-09-17 | 2000-11-14 | Pfizer Inc. | Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines |
| GT199900147A (es) * | 1998-09-17 | 1999-09-06 | 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas. | |
| US6462091B1 (en) | 1998-12-23 | 2002-10-08 | G.D. Searle & Co. | Combinations of cholesteryl ester transfer protein inhibitors and HMG coA reductase inhibitors for cardiovascular indications |
-
1999
- 1999-09-06 GT GT199900147A patent/GT199900147A/es unknown
- 1999-09-07 US US09/391,313 patent/US6140343A/en not_active Expired - Fee Related
- 1999-09-08 PA PA19998481201A patent/PA8481201A1/es unknown
- 1999-09-08 GC GCP1999273 patent/GC0000108A/xx active
- 1999-09-10 EA EA200100249A patent/EA005761B1/ru not_active IP Right Cessation
- 1999-09-10 SV SV1999000150A patent/SV1999000150A/es not_active Application Discontinuation
- 1999-09-10 HU HU0103512A patent/HUP0103512A3/hu unknown
- 1999-09-10 DK DK99940426T patent/DK1114032T3/da active
- 1999-09-10 JP JP2000574075A patent/JP3561474B2/ja not_active Expired - Fee Related
- 1999-09-10 DE DE69917790T patent/DE69917790T2/de not_active Expired - Fee Related
- 1999-09-10 CO CO99057641A patent/CO5290250A1/es not_active Application Discontinuation
- 1999-09-10 OA OA1200100062A patent/OA11651A/en unknown
- 1999-09-10 CU CU20010051A patent/CU23053A3/es unknown
- 1999-09-10 HK HK02101447.5A patent/HK1039938A1/zh unknown
- 1999-09-10 CN CNA2004100049599A patent/CN1515259A/zh active Pending
- 1999-09-10 KR KR10-2001-7003416A patent/KR100422286B1/ko not_active Expired - Fee Related
- 1999-09-10 AP APAP/P/2001/002100A patent/AP1345A/en active
- 1999-09-10 AR ARP990104554A patent/AR030523A1/es active IP Right Grant
- 1999-09-10 BR BR9913855-7A patent/BR9913855A/pt not_active Application Discontinuation
- 1999-09-10 PT PT99940426T patent/PT1114032E/pt unknown
- 1999-09-10 PE PE1999000922A patent/PE20001054A1/es not_active Application Discontinuation
- 1999-09-10 ES ES99940426T patent/ES2221420T3/es not_active Expired - Lifetime
- 1999-09-10 HR HR20010200A patent/HRP20010200B1/xx not_active IP Right Cessation
- 1999-09-10 CA CA002344248A patent/CA2344248C/en not_active Expired - Fee Related
- 1999-09-10 TR TR2001/00780T patent/TR200100780T2/xx unknown
- 1999-09-10 NZ NZ509837A patent/NZ509837A/xx unknown
- 1999-09-10 CZ CZ2001954A patent/CZ2001954A3/cs unknown
- 1999-09-10 UA UA2001031791A patent/UA70960C2/uk unknown
- 1999-09-10 AT AT99940426T patent/ATE268324T1/de not_active IP Right Cessation
- 1999-09-10 GE GEAP19995804A patent/GEP20032973B/en unknown
- 1999-09-10 CN CN99811014A patent/CN1318057A/zh active Pending
- 1999-09-10 SI SI9930595T patent/SI1114032T1/xx unknown
- 1999-09-10 YU YU18101A patent/YU18101A/sh unknown
- 1999-09-10 WO PCT/IB1999/001534 patent/WO2000017165A1/en not_active Ceased
- 1999-09-10 EP EP99940426A patent/EP1114032B1/en not_active Expired - Lifetime
- 1999-09-10 ID IDW20010621A patent/ID27838A/id unknown
- 1999-09-10 AU AU54403/99A patent/AU747715B2/en not_active Ceased
- 1999-09-10 SK SK353-2001A patent/SK3532001A3/sk unknown
- 1999-09-10 MY MYPI99003926A patent/MY121405A/en unknown
- 1999-09-10 PL PL346830A patent/PL198124B1/pl not_active IP Right Cessation
- 1999-09-10 TW TW088115688A patent/TW502022B/zh not_active IP Right Cessation
- 1999-09-10 IL IL14138899A patent/IL141388A0/xx not_active IP Right Cessation
- 1999-09-10 EE EEP200100167A patent/EE200100167A/xx unknown
- 1999-09-13 DZ DZ990191A patent/DZ2891A1/xx active
- 1999-09-13 TN TNTNSN99170A patent/TNSN99170A1/fr unknown
- 1999-09-13 MA MA25766A patent/MA26689A1/fr unknown
-
2000
- 2000-09-27 US US09/671,221 patent/US6489478B1/en not_active Expired - Fee Related
-
2001
- 2001-02-14 CR CR6306A patent/CR6306A/es unknown
- 2001-02-23 IS IS5858A patent/IS2278B/is unknown
- 2001-03-01 ZA ZA200101745A patent/ZA200101745B/en unknown
- 2001-03-16 NO NO20011349A patent/NO319781B1/no not_active IP Right Cessation
- 2001-04-10 BG BG105429A patent/BG65101B1/bg unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR030523A1 (es) | Compuestos 1,2,3,4-tetrahidroquinolinas 2-sustituidas 4-amino sustituidas, su uso en la preparacion de medicamentos, composiciones farmaceuticas, y equipo que los contiene. | |
| AR044507A1 (es) | Compuestos de quinolina y quinoxalina | |
| AR042131A1 (es) | Compuestos de piperidina fenil sustituidas y su uso como activadores de ppar | |
| CO5370678A1 (es) | 1,2,3,4-tetrahidroquinolinas 2-sustituidas 4-carboxiamino sustituidas | |
| AR021482A1 (es) | Compuestos de 4-carboxiamino-1,2,3,4-tetrahidroquinolinas, composiciones farmaceuticas, kit, y uso de los mismos. | |
| AR076228A1 (es) | Piperidinas sustituidas como antagonistas de ccr3 | |
| AR059802A1 (es) | Compuestos y derivados de dibencilamina, combinaciones y composiciones farmaceuticas que los comprenden y el uso de estos derivados en el tratamiento de enfermedades mediadas por la actividad de cetp. | |
| DK0987251T3 (da) | 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinoliner som CETP-inhibitorer | |
| AR053232A1 (es) | Derivados de piridina condensadas, composiciones farmaceuticas que los contienen y su empleo en la fabricacion de agentes terapeuticos antiinflamatorios y para el tratamiento de enfermedades relacionadas con el sistema inmunologico. | |
| KR950704228A (ko) | 선택적 포스포디에스테르가수분해효소 iv형(pde_iv) 저해제로서의 카테콜 디에테르(catecol diethers as selective pde_iv inhibitors) | |
| EP0712389A4 (en) | THERAPEUTIC COMPOUND FATTY ACID CONJUGATES | |
| AR057996A1 (es) | Compuestos, composiciones pesticidas y metodo par combatir pestes | |
| PT81586B (pt) | Processo para a preparacao de derivados de benzoxazol e benzotiazolamina e de composicoes farmaceuticas que os contem | |
| ES2149188T3 (es) | Paclitaxels 6,7-modificados. | |
| AR060957A1 (es) | Derivados de tiazolo-pirimidina / piridina-urea | |
| AR072578A1 (es) | Compuestos de piperidina puenteada tipo quinoxalina sustituida y los usos de los mismos | |
| CO6160236A2 (es) | Inhibidor de quinasa | |
| AR012488A1 (es) | Un compuesto derivado de quino- y quinazolinas antagonistas del factor liberador de corticotropina, un procedimiento para su preparacion, unacomposicion que los comprende, un procedimiento para la preparacion de dicha composicion, intermediarios y el uso de dichos compuestos para la fabricacion | |
| IL143545A0 (en) | Thrombin inhibitors | |
| AR066911A1 (es) | Derivados de piperidina / piperazina | |
| CO5080750A1 (es) | Derivados de benzimidina, composiciones farmaceuticas que los contienen y su uso como antitromboticos | |
| HUT64529A (en) | Method for producing flu orinated derivatives of taxole and preparations contaxole preparations containing said compounds as active agent | |
| AR127783A1 (es) | Composición farmacéutica que comprende compuestos de drogas biofarmacéuticas | |
| AR045821A1 (es) | Derivados de benzimidazol composiciones que los contienen preparacion de los mismos y usos de los mismos | |
| AR054707A1 (es) | Derivados de octahidropirrolo 3,4-c pirrol, un procedimiento para su preparacion, una composicion farmaceutica y uso del compuesto para la fabricacion de un medicamento |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |